CLDX as reported
Celldex Therapeutics, Inc. reported $158K of revenue over the trailing twelve months, −97% on the year before. 9 reported series are charted on this page, each one as filed.
$158K
Revenue, trailing twelve months · to Q2 2026 · −97% against the twelve months before
- Net Income
- −$301M
Net Income · +51% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- −$242M
Free Cash Flow · +28% year on year · trailing twelve months to Q2 2026
- EPS
- −$4.36
EPS · +45% year on year · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $158K | −97% | Q2 2026 |
| Net Income | −$301M | +51% | Q2 2026 |
| EPS | −$4.36 | +45% | Q2 2026 |
| Op Margin | −6044% | n/a | Q2 2025 · 4 quarters behind |
| Net Margin | −5205% | n/a | Q2 2025 · 4 quarters behind |
| ROE | −48% | n/a | Q2 2026 |
| ROA | −43% | n/a | Q2 2026 |
| ROIC | −146% | n/a | Q1 2013 · 53 quarters behind |
| Free Cash Flow | −$242M | +28% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Celldex Therapeutics, Inc. (CLDX) - Revenue & ProfitRevenue & ProfitCelldex Therapeutics, Inc. (CLDX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com